Reproductive Sciences

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

http://mc.manuscriptcentral.com/rsci

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Rocconi, R. P.
Right arrow Articles by Huh, W. K.
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Reproductive Sciences, Vol. 15, No. 3, 321-326 (2008)
DOI: 10.1177/1933719108316390
© 2008 SAGE Publications

Lipoxygenase Pathway Receptor Expression in Ovarian Cancer

Rodney P. Rocconi, MD

Department of Obstetrics and Gynecology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, rocconi{at}usouthal.edu

Tyler O. Kirby, MD

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Alabama

Robert S. Seitz, PhD

Applied Genomics, Inc, Huntsville Alabama

Rod Beck, PhD

Applied Genomics, Inc, Huntsville Alabama

J. Michael Straughn, Jr, MD

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Alabama

Ronald D. Alvarez, MD

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Alabama

Warner K. Huh, MD

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Alabama

Objective: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX—based therapy. Study design: Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). Results: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. Conclusions: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.

Key Words: Ovarian cancer • lipoxygenase inhibitor • LY293111 • leukotriene receptors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?